Replimune Q2 net loss widens

Replimune

06/11/2025 13:14

Overview

Replimune fiscal Q2 net loss widens to $83.1 mln from $53.1 mln last year

Cash position decreases to $323.6 mln from $483.8 mln as of March 31, 2025

Outlook

Replimune expects FDA decision on RP1 BLA by April 2026

Company plans to fund operations into late 2026

Result Drivers

R&D EXPENSES - Increase in R&D expenses due to higher costs for RP1 and RP2 studies, including IGNYTE-3

FDA ACCEPTANCE - FDA accepted BLA resubmission for RP1, potential approval progress

CLINICAL TRIAL PROGRESS - Positive data from IGNYTE trial for RP1 plus nivolumab in skin cancers

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$83.10 mln
Q2 Basic EPS
-$0.90
Q2 Cash & Investments
$323.60 mln
Q2 Operating Expenses
$84.29 mln
Q2 Operating Income
-$84.29 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Replimune Group Inc is $12.50, about 31.4% above its November 5 closing price of $8.58

Press Release: ID:nGNX8P8Bvy

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)